Femme Homme | 18 ans et plus
- | Pays :
- France
- | Organes :
- Sein
- | Spécialités :
- Chimiothérapie
Extrait
A multicenter randomized study to compare the combination trastuzumab and capecitabine, with or without pertuzumab on progression free survival, as 2nd-line treatment in patients with HER2-positive metastatic breast cancer that has progressed after previous treatment with trastuzumab.
Extrait Scientifique
en cours d'intégration;